The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
本发明涉及一种新颖的、非次级甾体的、羟基取代的、碳链连接的二芳基化合物,具有
维生素D受体(VDR)调节活性,且其对血
钙升高的作用比1α,25-二羟基
维生素D3小。这些化合物可用于治疗骨病和牛皮癣。